Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.61 |
| ▸ | ALB | P02768 | 2/20 | 0.60 |
| ▸ | CA9 | Q16790 | 12/20 | 0.58 |
| ▸ | CA1 | P00915 | 11/20 | 0.58 |
| ▸ | CA2 | P00918 | 11/20 | 0.58 |
| ▸ | CA12 | O43570 | 6/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.56 |
| ▸ | CA7 | P43166 | 2/20 | 0.56 |
| ▸ | HTR3A | P46098 | 2/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18807599 | 1.00 | FOLH1 (0.61) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL20529844 | 1.00 | FOLH1 (0.61) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL31380586 | 1.00 | FOLH1 (0.61) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL19389433 | 0.96 | FOLH1 (0.58) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL22100260 | 0.95 | FOLH1 (0.59) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL13012837 | 0.93 | CA9 (0.60) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL24403901 | 0.91 | FOLH1 (0.55) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL20843781 | 0.90 | FOLH1 (0.56) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL17245299 | 0.90 | FOLH1 (0.56) | FOLH1ALBCA9CA1CA2 | |
| SCHEMBL13062332 | 0.90 | CA9 (0.57) | FOLH1ALBCA9CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348405-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSTY | 2023-11-02 | — | — | US | disclosed |
| US-11661402-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-11021450-B2 | PSMA targeted fluorescent agents for image guided surgery | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-06-01 | — | — | US | disclosed |
| US-20200216402-A1 | PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY | THE JOHNS HOPKINS UNIVERSITY | 2020-07-09 | — | — | US | disclosed |
| US-9776977-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2408755-B1 | Urea-based peptide compounds useful for detecting inter alia prostate cancer | UNIV JOHNS HOPKINS (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9056841-B2 | PSMA-targeting compounds and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-06-16 | — | — | US | disclosed |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-04-16 | — | — | US | disclosed |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
| WO-2010108125-A2 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11021450-B2 | PSMA targeted fluorescent agents for image guided surgery | KLK3, FOLH1, SPR | FOLH1 2/4885ALB 374/4885CA9 49/4885 |
| US-20120009121-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | FOLH1 1/4885ALB 2044/4885CA9 118/4885 |
| US-20230348405-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | KLK3, FOLH1, SPR | FOLH1 2/4885ALB 649/4885CA9 47/4885 |
| US-20150104387-A1 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | FOLH1, KLK3, PSMA2 | FOLH1 1/4885ALB 2044/4885CA9 118/4885 |
| US-20200216402-A1 | PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY | KLK3, FOLH1, SPR | FOLH1 2/4885ALB 374/4885CA9 49/4885 |
| US-11661402-B2 | PSMA-targeting compounds and uses thereof | KLK3, FOLH1, SPR | FOLH1 2/4885ALB 649/4885CA9 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.